China Universal Asset Management Co. Ltd. Purchases 6,405 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

China Universal Asset Management Co. Ltd. raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 64.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,381 shares of the company’s stock after purchasing an additional 6,405 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in CRISPR Therapeutics were worth $770,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of CRSP. Capital International Investors increased its holdings in shares of CRISPR Therapeutics by 27.8% in the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. SR One Capital Management LP acquired a new position in shares of CRISPR Therapeutics in the first quarter valued at about $71,496,000. Farallon Capital Management LLC acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at about $28,625,000. Avoro Capital Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the first quarter valued at about $28,599,000. Finally, Marshall Wace LLP acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at about $10,078,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on CRSP shares. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC decreased their target price on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Barclays decreased their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $75.19.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Trading Down 1.5 %

CRSP opened at $48.94 on Wednesday. The company’s 50 day moving average is $47.18 and its 200-day moving average is $52.60. CRISPR Therapeutics AG has a 1-year low of $38.16 and a 1-year high of $91.10. The company has a market cap of $4.16 billion, a P/E ratio of -17.99 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the prior year, the firm posted ($0.98) EPS. The company’s quarterly revenue was down 99.3% compared to the same quarter last year. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.